×
NexImmune Net Profit Margin 2020-2024 | NEXI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
NexImmune net profit margin from 2020 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
NexImmune Net Profit Margin 2020-2024 | NEXI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
NexImmune net profit margin from 2020 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$145.5B
Vertex Pharmaceuticals (VRTX)
$119.4B
Gilead Sciences (GILD)
$114.5B
Bristol Myers Squibb (BMY)
$113.1B
CSL (CSLLY)
$84.9B
Regeneron Pharmaceuticals (REGN)
$80.4B
GSK (GSK)
$70.4B
Argenex SE (ARGX)
$36.7B
Alnylam Pharmaceuticals (ALNY)
$31.7B
BioNTech SE (BNTX)
$28.6B
Illumina (ILMN)
$22.8B
Biogen (BIIB)
$21.9B
BeiGene (BGNE)
$17.5B
Moderna (MRNA)
$16.1B
Genmab (GMAB)
$13.3B
Incyte (INCY)
$13.2B
Insmed (INSM)
$12.8B
BioMarin Pharmaceutical (BMRN)
$12.6B
Bio-Techne Corp (TECH)
$12B
Sarepta Therapeutics (SRPT)
$11.8B
Exact Sciences (EXAS)
$11.3B
Vaxcyte (PCVX)
$10.9B
QIAGEN (QGEN)
$10.4B
Exelixis (EXEL)
$10B
Bio-Rad Laboratories (BIO.B)
$9.4B
Intra-Cellular Therapies (ITCI)
$8.8B
Repligen (RGEN)
$8.8B
Roivant Sciences (ROIV)
$8.6B
Ascendis Pharma (ASND)
$7.9B
Revolution Medicines (RVMD)
$7.6B